171 related articles for article (PubMed ID: 20401690)
1. Glycolysis inhibition decreases the levels of glutamate transporters and enhances glutamate neurotoxicity in the R6/2 Huntington's disease mice.
Estrada-Sánchez AM; Montiel T; Massieu L
Neurochem Res; 2010 Aug; 35(8):1156-63. PubMed ID: 20401690
[TBL] [Abstract][Full Text] [Related]
2. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters.
Estrada-Sánchez AM; Montiel T; Segovia J; Massieu L
Neurobiol Dis; 2009 Apr; 34(1):78-86. PubMed ID: 19168136
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.
Petr GT; Schultheis LA; Hussey KC; Sun Y; Dubinsky JM; Aoki C; Rosenberg PA
Eur J Neurosci; 2013 Aug; 38(3):2477-90. PubMed ID: 23586612
[TBL] [Abstract][Full Text] [Related]
4. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation.
Behrens PF; Franz P; Woodman B; Lindenberg KS; Landwehrmeyer GB
Brain; 2002 Aug; 125(Pt 8):1908-22. PubMed ID: 12135980
[TBL] [Abstract][Full Text] [Related]
5. Sustained metabolic inhibition induces an increase in the content and phosphorylation of the NR2B subunit of N-methyl-D-aspartate receptors and a decrease in glutamate transport in the rat hippocampus in vivo.
Camacho A; Montiel T; Massieu L
Neuroscience; 2007 Mar; 145(3):873-86. PubMed ID: 17331654
[TBL] [Abstract][Full Text] [Related]
6. Complete but not partial inhibition of glutamate transporters exacerbates cortical excitability in the R6/2 mouse model of Huntington's disease.
Estrada-Sánchez AM; Castro D; Portillo-Ortiz K; Jang K; Nedjat-Haiem M; Levine MS; Cepeda C
CNS Neurosci Ther; 2019 Apr; 25(4):509-518. PubMed ID: 30311425
[TBL] [Abstract][Full Text] [Related]
7. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects.
Faideau M; Kim J; Cormier K; Gilmore R; Welch M; Auregan G; Dufour N; Guillermier M; Brouillet E; Hantraye P; Déglon N; Ferrante RJ; Bonvento G
Hum Mol Genet; 2010 Aug; 19(15):3053-67. PubMed ID: 20494921
[TBL] [Abstract][Full Text] [Related]
8. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice.
Liévens JC; Woodman B; Mahal A; Spasic-Boscovic O; Samuel D; Kerkerian-Le Goff L; Bates GP
Neurobiol Dis; 2001 Oct; 8(5):807-21. PubMed ID: 11592850
[TBL] [Abstract][Full Text] [Related]
9. Dearth of glutamate transporters contributes to striatal excitotoxicity.
Brustovetsky T; Purl K; Young A; Shimizu K; Dubinsky JM
Exp Neurol; 2004 Oct; 189(2):222-30. PubMed ID: 15380474
[TBL] [Abstract][Full Text] [Related]
10. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
11. Oncostatin M promotes excitotoxicity by inhibiting glutamate uptake in astrocytes: implications in HIV-associated neurotoxicity.
Moidunny S; Matos M; Wesseling E; Banerjee S; Volsky DJ; Cunha RA; Agostinho P; Boddeke HW; Roy S
J Neuroinflammation; 2016 Jun; 13(1):144. PubMed ID: 27287400
[TBL] [Abstract][Full Text] [Related]
12. Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice.
Nicniocaill B; Haraldsson B; Hansson O; O'Connor WT; Brundin P
Eur J Neurosci; 2001 Jan; 13(1):206-10. PubMed ID: 11135020
[TBL] [Abstract][Full Text] [Related]
13. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
14. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity.
Shin JY; Fang ZH; Yu ZX; Wang CE; Li SH; Li XJ
J Cell Biol; 2005 Dec; 171(6):1001-12. PubMed ID: 16365166
[TBL] [Abstract][Full Text] [Related]
15. Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice.
Oláh J; Klivényi P; Gardián G; Vécsei L; Orosz F; Kovacs GG; Westerhoff HV; Ovádi J
FEBS J; 2008 Oct; 275(19):4740-55. PubMed ID: 18721135
[TBL] [Abstract][Full Text] [Related]
16. Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease.
Huang K; Kang MH; Askew C; Kang R; Sanders SS; Wan J; Davis NG; Hayden MR
Neurobiol Dis; 2010 Oct; 40(1):207-15. PubMed ID: 20685337
[TBL] [Abstract][Full Text] [Related]
17. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
[TBL] [Abstract][Full Text] [Related]
18. N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington's disease.
Wright DJ; Gray LJ; Finkelstein DI; Crouch PJ; Pow D; Pang TY; Li S; Smith ZM; Francis PS; Renoir T; Hannan AJ
Hum Mol Genet; 2016 Jul; 25(14):2923-2933. PubMed ID: 27179791
[TBL] [Abstract][Full Text] [Related]
19. Functional Indicators of Glutamate Transport in Single Striatal Astrocytes and the Influence of Kir4.1 in Normal and Huntington Mice.
Dvorzhak A; Vagner T; Kirmse K; Grantyn R
J Neurosci; 2016 May; 36(18):4959-75. PubMed ID: 27147650
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse.
Miller BR; Dorner JL; Shou M; Sari Y; Barton SJ; Sengelaub DR; Kennedy RT; Rebec GV
Neuroscience; 2008 Apr; 153(1):329-37. PubMed ID: 18353560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
